Testosterone for women is one of the fastest growing conversations in menopause care, and one of the most muddled. The short version: testosterone is a normal female hormone, not a male hormone that women borrow. Levels decline gradually from the twenties onwards, and for some women after menopause, low sexual desire that causes genuine distress can respond to carefully dosed testosterone alongside standard HRT. That is the use the evidence supports. The claims stretching beyond it, more energy, sharper thinking, easier weight control, are currently running well ahead of the trials. This article covers what testosterone actually does in women, what the research shows, how prescribing works in the UK when no licensed female product exists, and what realistic treatment and monitoring look like.
What does testosterone do in women?
Women make testosterone in the ovaries and adrenal glands, and before menopause they produce more of it each day than oestrogen. It contributes to sexual desire and arousal, helps maintain muscle and bone, and plays some part in mood and energy, although separating its effects from everything else that shapes those things is genuinely difficult. Unlike oestrogen, testosterone does not fall off a cliff at natural menopause. It declines slowly across adult life, so a woman in her forties already has roughly half the level she had in her twenties, and the change through the menopause transition itself is comparatively small. Surgical menopause is the exception: removing the ovaries takes away around half of the body's testosterone production overnight, which is why symptoms can be more abrupt in that group and why testosterone tends to be discussed earlier with them.
Does testosterone help menopause symptoms?
The strongest evidence is narrow and specific: low sexual desire that causes distress in postmenopausal women, sometimes labelled hypoactive sexual desire disorder. A large systematic review of randomised trials, which underpins the international position statement on testosterone for women, found modest but consistent improvements in desire, arousal, orgasm and sexual satisfaction, in the region of one additional satisfying sexual event per month. For everything else, mood, energy, cognition, muscle and bone, the same review judged the evidence insufficient to recommend treatment. UK guidance reflects this. The NICE menopause guideline supports considering testosterone for low sexual desire when HRT alone has not helped, and goes no further. If libido is the concern, it is worth reading about how testosterone and desire interact more broadly, because hormones are only one input among many.
How does testosterone prescribing work in the UK?
There is no testosterone product licensed for women in the UK, so prescribing is off-label: clinicians use gels or creams licensed for men at around a tenth of the male dose, typically a pea-sized amount of gel applied daily to the lower body. Off-label prescribing is lawful and common across medicine, but it does mean the prescriber takes on more responsibility, which is why some GPs prefer to refer to a menopause specialist rather than start it themselves. In practice, testosterone is usually considered after oestrogen-based HRT is established and low desire persists, rather than as a first or standalone treatment. If you are still weighing up HRT itself, our guide to HRT patches covers the main options. NHS availability varies considerably by area; regulated private menopause clinics also prescribe, and carry the same monitoring obligations when they do.
What results are realistic?
Testosterone is not a quick fix, and it is not a general tonic. Most specialists suggest a trial of three to six months before judging benefit, with the expectation of a modest lift in desire and sexual satisfaction rather than a transformation. If nothing has changed by six months, the usual advice is to stop rather than escalate. It is also worth naming clearly what testosterone has not been shown to do: trials do not support it for weight loss, and the evidence for energy, motivation and brain fog is too thin to treat on. Those symptoms are extremely common in the menopause transition and have many drivers, from disturbed sleep to low iron to mood; our complete guide to perimenopause symptoms maps them out. Treating the whole picture usually matters more than adding one hormone to it.
Monitoring and side effects
Sensible prescribing includes a blood test before starting and periodic checks afterwards, keeping total testosterone within the normal female range. At those levels side effects are uncommon and usually mild: acne, oilier skin and increased hair growth at the application site are the ones most often reported, and rotating the application site helps. Washing hands after applying gel avoids transferring it to partners or children. Voice changes and other masculinising effects are rare and linked to doses above the female range, which is precisely what monitoring exists to prevent. The honest limitation is time: good safety data covers a few years of use rather than decades, and the NHS overview of HRT treats testosterone for women as an area for specialist guidance. That is a reason for proper follow-up, not necessarily a reason to avoid treatment.
The bottom line on testosterone for women: a real hormone with a real but narrow evidence base, prescribed off-label in the UK at female-appropriate doses, most useful for distressing low sexual desire after menopause once oestrogen replacement is in place. Approach it with clear expectations, insist on baseline and follow-up blood tests, and review honestly at six months. And if desire is the problem, look at sleep, stress, relationships and other medicines too, because testosterone is rarely the whole story.
